CLINICAL TRIALS PROFILE FOR NEPAFENAC

All Clinical Trials for nepafenac

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00330798 ↗	A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief	Completed	Matthew Caldwell	Phase 4	2006-02-01	The purpose of this study is to compare healing times and subjective pain level responses of nepafenac to placebo after photo refractive keratomileusis (PRK) surgery.
NCT00330798 ↗	A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief	Completed	Alcon Research	Phase 4	2006-02-01	The purpose of this study is to compare healing times and subjective pain level responses of nepafenac to placebo after photo refractive keratomileusis (PRK) surgery.
NCT00333255 ↗	Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery	Completed	Alcon Research	Phase 3	2005-09-01	The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.
NCT00377546 ↗	Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%	Completed	Innovative Medical	Phase 4	1969-12-31	To compare the penetration of three different NSAIDs.
NCT00405730 ↗	Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo	Completed	Alcon Research	Phase 3	2005-11-01	To evaluate the safety and efficacy of Nepafenac 1 mg/ml Eye Drops, Suspension, compared to Placebo and Ketorolac Trometamol 5 mg/ml Eye Drops, Solution for the prevention and treatment of ocular inflammation and ocular pain after cataract extraction with IOL implantation
NCT00407017 ↗	Therapeutic Variables in Cataract Surgery	Completed	Innovative Medical	Phase 4	1969-12-31	The purpose of this study is to compare patient outcomes in following cataract surgery in patients randomized to one of two surgical kits.
NCT00494494 ↗	Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery	Completed	Research to Prevent Blindness	Phase 4	2007-06-01	Purpose: Study the effect of nepafenac ophthalmic suspension 0.1% to prevent post-operative cystoid macular edema following uncomplicated cataract surgery Participants: Patients having cataract surgery at UNC who meet eligibility criteria Procedures (methods): Patients will have pre and post-operative vision measured and optical coherence tomography (OCT) testing, also cataract density and intraoperative phacoemulsification parameters including ultrasound power and ultrasound time will be measured. Patients will be randomized into two groups. Group 1 will be treated with standard post-operative cataract management. Group 2 will be treated with standard post-operative cataract management plus topical nepafenac for one month. Post-operative macular thickness will be studied by analyzing the visual acuity and OCT measurements at two months post surgery.

Clinical Trial Conditions for nepafenac

Condition Name

Condition Name for nepafenac
Intervention	Trials
Cataract	12
Macular Edema	5
Cystoid Macular Edema	4
Diabetic Macular Edema	3

Condition MeSH

Condition MeSH for nepafenac
Intervention	Trials
Cataract	20
Macular Edema	15
Edema	7
Inflammation	7

Clinical Trial Locations for nepafenac

Trials by Country

Trials by Country for nepafenac
Location	Trials
United States	19
India	3
Brazil	3
Malaysia	2
Mexico	2

Trials by US State

Trials by US State for nepafenac
Location	Trials
Texas	5
California	3
Wisconsin	1
New York	1
Kentucky	1

Clinical Trial Progress for nepafenac

Clinical Trial Phase

Clinical Trial Phase for nepafenac
Clinical Trial Phase	Trials
PHASE4	2
Phase 4	21
Phase 3	10

Clinical Trial Status

Clinical Trial Status for nepafenac
Clinical Trial Phase	Trials
Completed	35
Unknown status	5
RECRUITING	3

Clinical Trial Sponsors for nepafenac

Sponsor Name

Sponsor Name for nepafenac
Sponsor	Trials
Alcon Research	11
Allergan	3
Bausch & Lomb Incorporated	3

Sponsor Type

Sponsor Type for nepafenac
Sponsor	Trials
Other	43
Industry	22

NEPAFENAC: Clinical Trials Update, Market Analysis and Projections

Last updated: April 29, 2026

What is NEPAFENAC’s regulatory and clinical status?

NEPAFENAC is a topical nonsteroidal anti-inflammatory drug (NSAID) used to reduce inflammation and pain. This profile is consistent with the established clinical role of nepafenac-containing ophthalmic products (typically for post-cataract surgery outcomes), but the request requires a NEPAFENAC-specific clinical trials update, including trial identifiers, endpoints, recruitment status, sponsors, and dates. No NEPAFENAC-specific trial dataset is provided in the prompt, and no external trial registry data can be reliably asserted without source material.

Which NEPAFENAC clinical trials are active, completed, or pending?

No NEPAFENAC-specific trial list, NCT numbers, investigational dosing regimens, comparator arms, or readouts are available in the provided materials. A complete trials update requires trial-by-trial sourcing (e.g., ClinicalTrials.gov or equivalent) and result publications, which cannot be produced from the prompt alone.

What is NEPAFENAC’s market size and share potential?

A market analysis and forecast for “NEPAFENAC” also requires product-specific scoping: geography, branded vs generic status, approved indications, reference products, pricing inputs, and channel assumptions. The prompt does not provide those inputs, and NEPAFENAC can refer to multiple commercial embodiments depending on territory and brand naming conventions.

Given that the prompt does not include (1) country coverage, (2) branded status and launch history, (3) approved label timing and endpoints, (4) current competitive set composition, or (5) pricing and utilization baselines, a defensible quantitative market forecast cannot be completed.

---

What can be concluded from available information without inventing numbers?

Only the following fact pattern can be stated without fabricating trial or market figures:

• NEPAFENAC is a topical ophthalmic NSAID used for ocular inflammation/pain control in the post-procedural setting (commonly cataract surgery in clinical practice for nepafenac-class drugs).

Everything else requested in the brief is contingent on NEPAFENAC-specific evidence that is not present in the input.

---

Market analysis framework (inputs required to compute projections)

A projection model for an ophthalmic nepafenac product typically depends on:

• Indication incidence: cataract procedure volume and related post-op inflammation incidence assumptions
• Penetration: share of patients receiving NSAID prophylaxis and adherence to dosing schedules
• Pricing: wholesale acquisition cost (WAC) or net price by geography, dispensing size, rebates
• Competitor dynamics: alternatives by mechanism/class, formulary placement, and generic entry timing
• Regulatory constraints: approved label (e.g., prophylaxis vs treatment), age cohorts, and tapering guidance
• Lifecycle factors: patent status, exclusivity, and switch rates after generic launches

No NEPAFENAC-specific values are supplied, so the model cannot be instantiated.

---

Key takeaways

• NEPAFENAC is an ophthalmic NSAID used for ocular inflammation and pain control, typically in post-procedural care.
• A complete “clinical trials update” and a quantitative “market analysis and projection” cannot be produced from the prompt because NEPAFENAC-specific trial registry data and market inputs (label, geographies, pricing, competitor set, and utilization baselines) are not provided.

---

FAQs

1. Is NEPAFENAC currently used in ophthalmology?
   Yes. Nepafenac is an ophthalmic NSAID used to manage ocular inflammation and pain, commonly in post-procedure care settings.

2. What endpoints do NEPAFENAC trials usually evaluate?
   Ophthalmic anti-inflammatory and pain outcomes are typical, such as anterior chamber inflammation reduction and related pain scores, depending on the label and study design.

3. Can you provide NEPAFENAC market size figures?
   Not from the provided information. Market sizing requires geography, indication label scope, and pricing and utilization baselines.

4. Do NEPAFENAC products face generic or competitive pressure?
   Competitive pressure depends on territory-specific patent and approval status and the presence and timing of generic or alternative NSAIDs.

5. What is the fastest way to build a credible forecast for NEPAFENAC?
   Create a territory-by-territory model using cataract procedure volume, NSAID penetration rates by payer/formulary, net price, and generic entry timing tied to the specific marketed product.

---

References

[1] No sources were provided in the prompt.